NEW YORK, July 22, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc.
(NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Theravance Inc.
(NASDAQ: THRX), and NewLink Genetics Corporation (NASDAQ: NLNK).
Free research report on Amgen can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=AMGN On
Tuesday, July 21, 2015, the NASDAQ
Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial
Average declined 1.00%, to finish the day at 17,919.29, and the
S&P 500 closed at 2,119.21, down 0.43%. The losses were broad
based as seven out of nine sectors ended the session in negative.
Register for your complimentary reports at the links given below.
On Tuesday, shares in Amgen Inc. recorded a trading volume of
2.67 million shares, lower than their three months average volume
of 3.17 million shares. The stock ended the day 0.39% lower at
$163.70. Shares of the company traded
at a PE ratio of 22.09. Although, Amgen Inc.'s stock has lost 2.35%
in the previous three months, it has advanced 1.85% in the last one
month and 3.82% on YTD basis. The company is trading above its
50-day and 200-day moving averages by 3.38% and 4.37%,
respectively. Furthermore, shares of Amgen Inc. have a Relative
Strength Index (RSI) of 60.91. Sign up and read the free notes on
AMGN at:
https://www.EquityResearchInstitute.com/reports?keyword=AMGN
Exelixis Inc.'s stock gained 2.89%, to close Tuesday's session
at $6.05. The stock recorded a
trading volume of 22.10 million shares, much above its three months
average volume of 4.31 million shares. Over the last one month and
the previous three months, Exelixis Inc.'s shares have surged
57.55% and 97.07%, respectively. Additionally, the stock has
rallied 320.14% since the start of this year. The company is
trading 70.31% and 144.98% above its 50-day and 200-day moving
averages, respectively. Furthermore, Exelixis Inc.'s stock has an
RSI of 84.04. The complimentary notes on EXEL can be downloaded in
PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=EXEL
XOMA Corp.'s stock finished Tuesday's session 2.77% lower at
$4.39. A total of 3.69 million shares
were traded, which was above its three months average volume of
3.21 million shares. Over the last one month and the previous three
months, XOMA Corp.'s shares have surged 13.27% and 19.75%,
respectively. Additionally, the stock has gained 22.42% since the
beginning of 2015. The company's shares are trading above their
50-day and 200-day moving averages by 15.63% and 13.27%,
respectively. XOMA Corp.'s stock has an RSI of 57.02. Register for
free on Equity Research Institute and access the latest research on
XOMA at:
https://www.EquityResearchInstitute.com/reports?keyword=XOMA
On Tuesday, shares in Theravance Inc. ended the session 0.62%
lower at $15.92. The stock reported a
trading volume of 0.32 million shares, below its three months
average volume of 0.60 million shares. Theravance Inc.'s shares
have lost 15.25% in the last one month and 4.27% in the previous
three months. However, the stock has gained 12.51% on YTD basis.
The stock is trading 0.61% above its 200-day moving average.
Moreover, shares of Theravance Inc. have an RSI of 39.56. The
complete research on THRX is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=THRX
NewLink Genetics Corp.'s stock edged 0.73% lower, to close the
day at $54.24. The stock recorded a
trading volume of 0.38 million shares, below its three months
average volume of 0.60 million shares. Over the last one month and
over the past three months, NewLink Genetics Corp.'s shares have
gained 21.21% and 1.97%, respectively. Furthermore, the stock has
advanced 36.45% since the start of this year. The company's shares
are trading 20.32% above their 50-day moving average and 30.31%
above their 200-day moving average. Additionally, NewLink Genetics
Corp. traded at a PE ratio of 18.45 and has an RSI of 73.25. Free
in-depth research on NLNK is available at:
https://www.EquityResearchInstitute.com/reports?keyword=NLNK
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com